Rocket Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Sarbani Chaudhuri, See Remarks of Rocket Pharmaceuticals, Inc., sold 4,701 shares of common stock on August 11, 2026 for $3.50 per share.
NASDAQ
Christopher James Stevens, Chief Operating Officer of Rocket Pharmaceuticals, Inc., reported multiple transactions in common stock on August 3, 2026.
NASDAQ
David P Southwell, a Director of Rocket Pharmaceuticals, Inc., reported a transaction in 150,000 shares of common stock on August 3, 2026.
NASDAQ
Roderick Wong, a Director and 10% Owner of Rocket Pharmaceuticals, reported transactions involving common stock and stock options.
NASDAQ
Rocket Pharmaceuticals Director Peter Fong acquired shares and stock options, with vesting dates set for June 2027.
NASDAQ
Rocket Pharmaceuticals Director Mikael Dolsten acquired stock options and restricted stock units, indicating continued investment and commitment to the company.
NASDAQ
Rocket Pharmaceuticals Director Fady Ibraham Malik acquired 22,862 shares of common stock and was granted options for 64,860 shares.
NASDAQ
Rocket Pharmaceuticals Director David P. Southwell acquired restricted stock units and stock options, indicating continued investment and commitment to the company.
NASDAQ
Rocket Pharmaceuticals reports a Form 4 filing detailing stock transactions by Director Carsten Boess, including the acquisition of restricted stock units and stock options.
NASDAQ
Rocket Pharmaceuticals officer John Militello participated in an option exchange program, cancelling underwater options for new grants at $3.00 per share.
NASDAQ
Rocket Pharmaceuticals CEO Gaurav Shah reported transactions involving the purchase and sale of company stock, including exercising stock options.
NASDAQ
Rocket Pharmaceuticals CEO Gaurav Shah sold 2,409 shares of common stock for $3.014 each to cover tax obligations from vested Restricted Stock Units.
NASDAQ
Rocket Pharmaceuticals, Inc. reports that General Counsel Martin Wilson sold shares to cover tax obligations related to vested Restricted Stock Units.
NASDAQ
Rocket Pharmaceuticals officer John Militello sold shares to cover tax obligations related to vesting Restricted Stock Units.
NASDAQ
Rocket Pharmaceuticals, Inc. reports that General Counsel Martin Wilson sold 3,361 shares of common stock to cover tax obligations related to vested Restricted Stock Units.
NASDAQ
Rocket Pharmaceuticals CEO Gaurav Shah sold 2,728 shares of common stock for $3.60 per share to cover tax withholding obligations related to vesting Restricted Stock Units.
NASDAQ
Sarbani Chaudhuri, Chief Commercial & Medical Affairs Officer at Rocket Pharmaceuticals, sold 17,650 shares to cover tax obligations.
NASDAQ
Rocket Pharmaceuticals' Chief Medical Officer, Syed Ali-aamir Rizvi, increased his beneficial ownership through new grants of Restricted Stock Units and stock options.
NASDAQ
Rocket Pharmaceuticals' Chief Operating Officer, Christopher James Stevens, acquired 61,963 Restricted Stock Units and 93,037 stock options.
NASDAQ
Sarbani Chaudhuri, Chief Commercial & Medical Affairs Officer at Rocket Pharmaceuticals, received substantial equity awards including Restricted Stock Units and stock options.
NASDAQ
Elisabeth Bjork, a Director at Rocket Pharmaceuticals, Inc., acquired 10,000 shares of common stock at $3.44 per share, increasing her direct beneficial ownership.
NASDAQ
Rocket Pharmaceuticals' Chief Science Officer, Jonathan David Schwartz, sold 2,545 shares of company stock.
NASDAQ
Rocket Pharmaceuticals CEO Gaurav Shah sold 6,276 shares of common stock for $2.983 per share, as disclosed in a recent Form 4 filing.
NASDAQ
Rocket Pharmaceuticals' VP of Finance, John Militello, sold 1,086 shares of common stock on November 18, 2025, at $2.983 per share, as part of a pre-arranged 10b5-1 plan.
NASDAQ
Rocket Pharmaceuticals' General Counsel, Martin Wilson, sold 1,646 shares of common stock at $2.983 per share.
NASDAQ
Rocket Pharmaceuticals' General Counsel, Martin Wilson, reported the planned acquisition of 100,000 Restricted Stock Units, increasing his beneficial ownership.
NASDAQ
John Militello, VP of Finance at Rocket Pharmaceuticals, sold 28,918 shares of common stock for approximately $114,500 under a pre-arranged trading plan.
NASDAQ
Rocket Pharmaceuticals' Chief Medical Officer, Syed Ali-aamir Rizvi, significantly increased his beneficial ownership through new restricted stock unit and stock option grants.
NASDAQ
Rocket Pharmaceuticals Director Peter Fong was granted 53,333 restricted stock units, aligning his interests with long-term shareholder value.
NASDAQ
RTW Investments, LP and Roderick Wong reported the settlement of several equity swaps in Rocket Pharmaceuticals, resulting in no net change to their aggregate beneficial ownership.